Ozempic is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for weight loss. They contain different active ingredients (semaglutide vs. tirzepatide), work through different mechanisms, and are made by different companies. If your goal is weight loss, the appropriate FDA-approved medications are Wegovy (semaglutide) or Zepbound (tirzepatide).
Why people compare Ozempic and Zepbound
The internet is full of Ozempic-vs-Zepbound comparisons, but they’re comparing two things that aren’t really meant to be compared. Ozempic is a diabetes drug that causes weight loss as a secondary effect. Zepbound is a weight loss drug by design.
The confusion makes sense. Both are injectable GLP-1-related medications. Both cause significant weight loss. And Ozempic has become the public shorthand for all GLP-1 medications thanks to media coverage, celebrity use, and its catchier brand name. But from a clinical and insurance perspective, the distinction matters enormously.
Ozempic contains semaglutide, made by Novo Nordisk. Its FDA-approved indication is improving blood sugar in type 2 diabetes. Its maximum dose (2.0 mg) is lower than the weight-loss-specific version, Wegovy (2.4 mg).
Zepbound contains tirzepatide, made by Eli Lilly. It’s FDA-approved specifically for chronic weight management in adults with a BMI of 30+ (or 27+ with a weight-related comorbidity). It works through a dual GIP/GLP-1 mechanism that Ozempic doesn’t have.
The key difference: FDA indication
This isn’t a technicality. FDA indication determines:
- Insurance coverage. Ozempic is covered under diabetes benefits with a diabetes diagnosis. Zepbound is covered under weight management benefits with a qualifying BMI. Using Ozempic off-label for weight loss often means no coverage and full out-of-pocket cost.
- Clinical monitoring. Diabetes medications are dosed and monitored for glycemic targets. Weight loss medications are dosed and monitored for weight reduction and metabolic health outcomes.
- Dosing. Ozempic maxes out at 2.0 mg. Its weight-loss counterpart Wegovy goes to 2.4 mg. Zepbound goes up to 15 mg of tirzepatide, which is the same dose range as its diabetes counterpart Mounjaro.
The real comparison isn’t Ozempic vs. Zepbound. It’s Wegovy vs. Zepbound — two medications actually approved for the same purpose.
Side-by-side comparison
| Feature | Ozempic | Zepbound |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA indication | Type 2 diabetes | Chronic weight management |
| Mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Dose range | 0.25–2.0 mg | 2.5–15 mg |
| Weight loss data | ~5–7% (SUSTAIN trials, secondary endpoint) | ~22.5% (SURMOUNT-1, primary endpoint) |
| CV benefit | MACE reduction (SELECT trial via Wegovy) | SURPASS-CVOT ongoing |
| Sleep apnea | Not studied for this indication | FDA-approved for moderate-to-severe OSA |
| Vial option | No (pen only) | Yes (single-dose vials available) |
| Insurance for weight loss | Generally not covered (off-label) | Covered by many plans with PA |
| Weight-loss equivalent | Wegovy (semaglutide 2.4 mg) | Already approved for weight loss |
Weight loss figures are averages from clinical trials. Individual results depend on dose, duration, diet, and overall program adherence.
The right path for weight loss
If you’re researching Ozempic for weight loss, here’s the clinical reality: the medication you actually want is either Wegovy or Zepbound, depending on which molecule and mechanism is the best fit.
- You want the same active ingredient as Ozempic, but at the FDA-approved weight loss dose
- Cardiovascular protection matters (FDA-approved MACE reduction)
- Your insurance covers Wegovy or you qualify for savings programs
- You have a history with semaglutide and know you tolerate it well
- Maximum weight loss is the priority (tirzepatide produces more weight loss in trials)
- You have obstructive sleep apnea (Zepbound has an OSA indication)
- You prefer the option of vial dosing alongside pen injections
- Your insurance covers Zepbound or you qualify for Lilly savings
Using Ozempic off-label for weight loss creates real problems. Insurance won’t cover it without a diabetes diagnosis. If you lose weight and no longer “need” it for diabetes, coverage can be pulled. And you’re capped at a lower dose than what’s been studied for weight loss. Starting with the right FDA-approved medication — Wegovy or Zepbound — avoids all of these issues.
How PEAK approaches this
PEAK does not prescribe Ozempic for weight loss. We don’t prescribe any medication off-label when an FDA-approved weight loss version exists. This isn’t a limitation — it’s a deliberate choice that protects our patients.
We prescribe Wegovy and Zepbound, the FDA-approved weight loss versions of semaglutide and tirzepatide. Both are clinically proven for chronic weight management. Both have better insurance pathways when prescribed for their intended indication. And both are dosed appropriately for weight loss rather than diabetes.
If you’re currently on Ozempic and interested in transitioning to a proper weight loss medication, our clinical team can evaluate your situation and recommend the best path forward. Schedule a consultation to discuss your options.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
